BROMURO DE TIOTROPIO PDF

Further information on drug naming conventions: International Nonproprietary Names. Important Notice: The Drugs. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you.

Author:Fera Nelmaran
Country:Norway
Language:English (Spanish)
Genre:Business
Published (Last):23 September 2004
Pages:275
PDF File Size:15.62 Mb
ePub File Size:11.66 Mb
ISBN:420-8-77784-808-5
Downloads:94970
Price:Free* [*Free Regsitration Required]
Uploader:Nam



Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly.

Introduction: In the last decades chronic obstructive pulmonary disease COPD has an increasing occurrence in Mexico, making it an important area of expenditure for the health sector.

As control of exacerbations are a keystone from the clinical and economic point of view, it's important to evaluate the anticholinergics to define which is the most cost-effective. Material and methods: A Markov model was developed with a time horizon of 1 year.

View PDF. Save to Library. Create Alert. Launch Research Feed. Share This Paper. Topics from this paper. Keystone effect Markov chain Disease gene identification. References Publications referenced by this paper. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Jan B. Wolfgang Schramm , D. Haake , Andreas Brandt Medicine Praxis Robert Beck , Stephen G.

Related Papers. Abstract Topics 15 References Related Papers. By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy , Terms of Service , and Dataset License.

FUSARO MI NOVIA PDF

Tiotropium Bromide

.

BULGAKOV MAESTRUL SI MARGARETA PDF

Costo-efectividad de bromuro de tiotropio en la enfermedad pulmonar obstructiva crónica*

.

Related Articles